Incyte (INCY) Q4 Earnings: Revenue and EPS Outlook

Incyte Corporation (NASDAQ:INCY) is scheduled to report earnings before the market opens on February 06, 2026. Last quarter, the biopharma company posted revenue of $1.37 billion, up 20% year-on-year, and beat revenue and EPS estimates. For Q4 2025, analysts expect revenue to grow 14.8% YoY to $1.35 billion and adjusted earnings of $1.95 per share, down from the 16.3% growth in the same quarter of 2024. Incyte has missed revenue estimates just once in the past two years, with an average positive beat of 3.4% on average. Biotechnology peers showed mixed results: Regeneron revenue rose 2.5% YoY and beat estimates by 2.7%, while Biogen declined 7.1% YoY but topped estimates by 3.6%. Incyte is up 1.9% over the past month while the sector averaged -3.1% and has an average analyst price target of $104.23 versus its current share price of $108.37.